title: Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.
abstract: Due to influenza viruses continuously displaying antigenic variation, current seasonal influenza vaccines must be updated annually to include the latest predicted strains. Despite all the efforts put into vaccine strain selection, vaccine production, testing, and administration, the protective efficacy of seasonal influenza vaccines is greatly reduced when predicted vaccine strains antigenically mismatch with the actual circulating strains. Moreover, preparing for a pandemic outbreak is a challenge, because it is unpredictable which strain will cause the next pandemic. The European Commission has funded five consortia on influenza vaccine development under the Seventh Framework Programme for Research and Technological Development (FP7) in 2013. The call of the EU aimed at developing broadly protective influenza vaccines. Here we review the scientific strategies used by the different consortia with respect to antigen selection, vaccine delivery system, and formulation. The issues related to the development of novel influenza vaccines are discussed.
authors: Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. Electronic address: h.liu@rug.nl.
authors: Heng
authors: H
authors: Liu
authors: Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
authors: Henderik W
authors: HW
authors: Frijlink
authors: Department of Medical Microbiology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
authors: Anke
authors: A
authors: Huckriede
authors: Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
authors: Eva
authors: E
authors: van Doorn
authors: Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
authors: Ed
authors: E
authors: Schmidt
authors: European Vaccine Initiative (EEIG), Im Neuerheimer Feld 307, 69120 Heidelberg, Germany.
authors: Odile
authors: O
authors: Leroy
authors: Erasmus University Medical Center Rotterdam (EMC), Dr. Molewaterplein 50, 3015 CE Rotterdam, The Netherlands.
authors: Guus
authors: G
authors: Rimmelzwaan
authors: The Institute of Virology and Immunology (IVI), Sensemattstrasse 293, CH-3147 Mittelhäusern, Switzerland.
authors: Keneth
authors: K
authors: McCullough
authors: iQur Limited, London Bioscience Innovation Centre, 2 Royal College Street, NW1-0NH London, United Kingdom.
authors: Mike
authors: M
authors: Whelan
authors: Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. Electronic address: e.hak@rug.nl.
authors: Eelko
authors: E
authors: Hak
mesh_terms: D035843:Biomedical Research / Q000191:economics; D005062:European Union; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000737:chemistry; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D058873:Pandemics / Q000517:prevention & control; D012109:Research Support as Topic
chemical_list: D007252:Influenza Vaccines
keywords: Broadly protective; Correlates of protection; EU consortia; Influenza; Vaccines